Compare Novavax Inc (NVAX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Otis Worldwide Corp — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Otis Worldwide Corp trades at $65.95 (market cap $25.17B). The key difference: Otis Worldwide Corp is far larger — about 13.8× Novavax Inc's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Otis Worldwide Corp for 66 Days on average.
| NVAX | OTIS | |
|---|---|---|
Market Cap | $1.82B | $25.17B |
Volume | 6,198,505 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $12.75 | $93.62 |
52-Week Low | $6.22 | $64.05 |
Typical Hold Time | 59 Days | 66 Days |
Enterprise Value | $1.39B | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Otis Worldwide trades at $66.11, up 0.56% today but near its 52-week low, with a bearish technical signal and mixed earnings history. The company reported revenue of $14.43B in 2025 with a net income margin of 10.17%, though recent quarters have seen EPS misses. Analyst consensus is split between Buy and Hold, with a price target of $87.00. News highlights margin pressures from China and labor costs, alongside CEO succession plans for 2027.
The outlook is cautious due to near-term margin headwinds and weak equipment demand, but the service segment's growth and dominant market position offer long-term stability. Risks include China exposure and cost inflation, while institutional buying and a discounted valuation present potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
